Kymera Investor Day Presentation Deck

Introduction to Kymera Clinical Stage Pipeline IRAK4 Degrader KT-474 Ph1 HV study: SAD/MAD data KT-474 Development in Immuno-inflammatory Diseases ● ● IRAKIMID Degrader KT-413 Update and Clinical Plans STAT3 Degrader KT-333 Update and Clinical Plans STAT3 Degraders in Immune-inflammation and Fibrosis Break Discovery Pipeline Principles and MDM2, New Degrader Program in Development Today's Agenda Expanding the Drugged Proteome: Kymera's Platform Kymera 2026 Vision Q&A KYMERA ©2021 KYMERA THERAPEUTICS, INC. Nello Mainolfi, Ph.D. Founder and Chief Executive Officer, Kymera Jared Gollob, M.D., Chief Medical Officer, Kymera Naimish Patel, M.D., SVP, Head of Global Development, Immunology and Inflammation, Sanofi Genzyme Ashwin Gollerkeri, M.D., SVP, Head of Development, Kymera Juliet Williams, Ph.D., SVP, Head of Biology, Kymera Chris De Savi, Ph.D., VP, Drug Discovery, Kymera Nello Mainolfi, Ph.D. Founder and Chief Executive Officer, Kymera Nello Mainolfi, Ph.D., Founder and Chief Executive Officer, Kymera Jared Gollob, M.D., Chief Medical Officer, Kymera Bruce Jacobs, CFA, MBA Chief Financial Officer, Kymera KYMERA R&D DAY - December 16th, 2021 PAGE 9

View entire presentation